Mitchell O. Finkelstein (high school research intern), presented this presentation during the 31st Annual International Prostate Cancer Update in July 2021, in Snowbird, Utah.
Read More
Steven E. Finkelstein, MD, FACRO, a radiation oncologist with Florida Cancer Affiliates in Panama City, Florida, discusses metastasis-directed therapy (MDT) as a potential treatment option for oligometastatic prostate cancer. He reviews typical management of metastatic cancer and describes how MDT can minimize the toxicity of systemic therapy, then addresses future treatment options with stereotactic ablative radiotherapy (SABR). Radiation and other local therapies are used for palliation of metastases but can also alter the course of tumor development. Dr. Finkelstein explains that MDT can be particularly beneficial in oligometastatic prostate cancer if the metastases are at a point where both the primary tumor and metastases can be treated together and likely cured. Lastly, he concludes that MDT via SABR could be employed concurrently with other treatments such as androgen deprivation therapy (ADT), chemotherapies, and radiopharmaceuticals, and that further research is necessary.
Read More
Steven E. Finkelstein, MD, FACRO, a radiation oncologist with Florida Cancer Affiliates in Panama City, Florida, discusses the growing field of brachytherapy-driven immunotherapy and its potential role in prostate cancer treatment. He goes on to discuss the mechanisms behind radiation-induced tumor death, the growing evidence behind the immunostimulatory effects of radiation, and a patent describing a radiation-based applicator and potential method for administering immunotherapy agents to cancerous tissue.
Read More
Steven E. Finkelstein, MD, FACRO, discusses the increasing prevalence of brachytherapy as an option for prostate cancer patients in need of radiation therapy, specifically in the recurrent space. Additionally, he addresses the limitations of the technique and the lack of studies directly comparing brachytherapy to other options.
Read More
Steven E. Finkelstein, MD, FACRO, describes how hydrogel spacing is becoming standard of care for prostate cancer radiotherapy. He reviews the clinical investigations of adjacent prostate indications, as well as indications in other organs throughout the body, for this technology.
Read More